Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancerKenichi Sugihara, Toshiaki Watanabe, Kei Muro et al.|International Journal of Clinical Oncology|2017Cited by 2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancerYojiro Hashiguchi, Kei Muro, Yutaka Saitō et al.|International Journal of Clinical Oncology|2019Cited by 2k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Federico Nasroulah, Takayuki Yoshino et al.|The Lancet Oncology|2015Cited by 954
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOSTakayuki Yoshino, Jean‐Yves Douillard, Dirk Arnold et al.|Annals of Oncology|2017Cited by 591
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Hideaki Bando et al.|Nature Medicine|2020Cited by 366